Intensive LDL Lowering Drove Greater Coronary Plaque Regression
A combination of rosuvastatin and ezetimibe produced larger reductions in coronary plaque volume than high-dose atorvastatin alone in a randomized trial of adults with stable chest pain and significant coronary artery disease. The imaging results matter because plaque burden is not a static marker of past injury; it reflects an active disease process that can respond to aggressive lipid lowering, especially before lesions become heavily calcified and structurally fixed.
The FLOWPROMOTE trial enrolled 104 adults in Denmark with more than 50% coronary artery narrowing confirmed by coronary computed tomography angiography. None had previously taken statins, a detail that likely made the cohort especially responsive to intensive LDL reduction. Participants were assigned for 18 months to either atorvastatin 40 mg daily or rosuvastatin 40 mg plus ezetimibe 10 mg daily, with coronary CTA repeated at baseline, 9 months, and study end to track plaque change over time.
The central pattern was straightforward. The more intensive combination lowered LDL cholesterol more deeply and produced greater plaque regression.
LDL Cholesterol Fell Further With the Two-Drug Regimen
LDL cholesterol declined by 65% in the combination arm, dropping from an average of 127.4 mg/dL to 42.5 mg/dL. In the atorvastatin group, LDL fell by 38%. Those biochemical differences were mirrored by the coronary imaging data: total plaque volume fell by 21.1% with rosuvastatin and ezetimibe versus 13.6% with atorvastatin alone.
This is the biologic logic of lipid management made visible on imaging. Statins reduce cholesterol synthesis in the liver, while ezetimibe limits intestinal absorption of cholesterol. Used together, the two drugs attack LDL from complementary directions, and the resulting reduction in circulating atherogenic particles appears to translate into less plaque volume inside the coronary arteries. Lead study author Martin Bødtker Mortensen, MD, PhD, described LDL lowering as the most likely explanation for the more pronounced regression rather than a unique plaque-shrinking effect from the drug combination itself.
The achieved LDL levels tell the story even more clearly. The combination arm reached about 1.1 mmol/L, compared with 1.8 mmol/L with atorvastatin alone. Lower achieved LDL was repeatedly associated with greater regression across the cohort, strengthening the case that depth of lipid lowering, not simply the choice of agent, drove the imaging benefit.
Noncalcified Plaque Responded Most Clearly
The most clinically interesting signal emerged in noncalcified plaque, the lipid-rich portion of atherosclerotic deposits that is generally considered more biologically active and more prone to rupture. Noncalcified plaque volume decreased by 28.2% with combination therapy and by 20% with atorvastatin. A reduction was seen in 51 of 52 participants receiving rosuvastatin and ezetimibe, compared with 39 participants in the statin-only group.
One sentence captures the practical implication: the higher-intensity regimen did not merely slow plaque growth, it drove change in the portion of plaque most associated with instability.
Rupture of vulnerable plaque can set off thrombus formation, acute coronary occlusion, and myocardial infarction. When a therapy reduces the lipid-rich component of plaque, it may be shifting the lesion toward a more stable structure, not just reducing its size. Mortensen characterized noncalcified plaque as the dangerous part of the underlying disease process, and the imaging findings fit that biological frame.
Calcification Rose While Disease Appeared to Stabilize
A modest increase in calcified plaque volume appeared in both groups. On first glance, that could seem counterintuitive. In coronary atherosclerosis, though, a rise in calcium does not automatically signal worsening disease. As plaque becomes more stable, lipid-rich material can diminish while calcium deposits become more prominent. In that setting, a denser, more calcified plaque may be less likely to rupture than an inflamed, lipid-laden one.
This compositional shift is one reason serial plaque imaging is useful. Total plaque volume matters, but plaque biology matters too. A lesion that becomes smaller and more calcified is not equivalent to one that remains soft and rupture-prone. The trial suggests that intensive LDL lowering may alter both dimensions at once: reducing the overall burden while moving the remaining plaque toward a more stable phenotype.
What the Trial Can and Cannot Prove
The cohort was small, and every participant had established coronary disease without prior statin exposure. Those features sharpen the internal signal but narrow the reach of the results. The data show that intensive lipid lowering can shrink plaque on imaging in this specific population. They do not show fewer heart attacks, strokes, or cardiovascular deaths.
That distinction is essential in cardiology. Imaging regression is encouraging because plaque burden and plaque composition are tightly linked to future events, but coronary CTA is still a surrogate endpoint. The trial did not measure hard clinical outcomes, so the benefit remains mechanistic rather than event-proven.
The findings also should not be mistaken for a blanket argument that every patient with high cholesterol needs two drugs. Treatment intensity still depends on cardiovascular risk, baseline LDL level, prior therapy, comorbidities, and tolerance. Patients with established coronary disease may be the group most likely to benefit from aggressive lowering, especially when plaque is still relatively lipid-rich and before calcification dominates the lesion.
Why the Imaging Signal Matters for Practice
The broader message is that atherosclerosis can regress when LDL is driven low enough. That matters because coronary disease is often treated as a one-way process once plaque has formed. This trial challenges that assumption, at least in part. In statin-naive patients with confirmed CAD, intensive therapy achieved substantial LDL reduction and measurable regression of total and noncalcified plaque over 18 months.
A single observational snapshot would not be enough to change practice. Repeated CTA at prespecified intervals strengthens confidence in the trajectory, and the consistency of the imaging protocol adds credibility to the serial measurements. Mortensen said further studies from this project are already underway to determine which plaque types shrink, how quickly the changes occur, and how plaque composition influences treatment response.
What remains unresolved is the endpoint that matters most to patients: whether deeper plaque regression on imaging will translate into fewer acute coronary events over time. The next step is not more enthusiasm; it is longer follow-up with hard outcomes and larger cohorts that can test whether the biologic gains seen here hold up in daily cardiovascular care.